
Climb Bio, Inc.
NASDAQ•CLYM
CEO: Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-08-10
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Contact Information
PMB #117, 2801 Centerville Road, 1st Floor, Wilmington, DE, 19808-1609, United States
866-857-2596
Market Cap
$287.74M
P/E (TTM)
-5.6
38.2
Dividend Yield
--
52W High
$5.19
52W Low
$1.05
52W Range
Rank49Top 66.7%
3.2
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q3 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.19+46.15%
4-Quarter Trend
FCF
-$12.25M+62.12%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Pipeline Advancement Milestones Met Budoprutug Phase 2 trial initiated across three indications. CLYM116 Phase 1 dosing expected by year-end 2025.
Nine-Month Net Loss Reduced Nine-month net loss narrowed substantially to $42.3M in 2025 from $65.5M in 2024, showing operational leverage.
Cash Runway Secured Through 2027 Cash, equivalents, and securities total $175.8M as of September 30, 2025. Sufficient funding projected through 2027.
Risk Factors
Continued Operating Losses Expected Anticipates substantial future losses; no product revenue source currently exists. Profitability remains highly uncertain.
Internal Control Material Weaknesses Material weaknesses in internal control over financial reporting remain unremediated as of September 30, 2025.
Reliance on Third-Party Suppliers Heavy reliance on third parties for manufacturing and clinical execution. Supply disruption risks development timelines.
Outlook
Budoprutug Clinical Data Expected Expect initial efficacy data from Budoprutug Phase 1b/2a trials in ITP and SLE in second half of 2026.
CLYM116 Phase 1 Completion Timeline Anticipate initial clinical data from CLYM116 Phase 1 trial in healthy volunteers in Australia by mid-2026.
Future Capital Requirements Anticipated Anticipates needing substantial financing in the future to fund operations beyond current cash runway projection.
Peer Comparison
Revenue (TTM)
AGEN$106.83M
$16.33M
$6.61M
Gross Margin (Latest Quarter)
100.0%
87.1%
51.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CLYM | $287.74M | -5.6 | -26.4% | 0.3% |
| CNTX | $132.31M | -5.2 | -30.9% | 0.2% |
| IKT | $118.57M | -3.2 | -57.2% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 24, 2026
EPS:-$0.19
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 6, 2025|Revenue: $0.00+0.0%|EPS: $-0.19+46.2%N/AForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 12, 2025|Revenue: $0.00+0.0%|EPS: $-0.13-92.8%N/AForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 14, 2025|Revenue: $0.00+0.0%|EPS: $-0.31+404.9%N/AForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 25, 2025|Revenue: $0.00+0.0%|EPS: $-1.53-17.7%N/AForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $0.00+0.0%|EPS: $-0.13-13.3%N/AForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 14, 2024|Revenue: $0.00+0.0%|EPS: $-1.81+852.6%N/AForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 15, 2024|Revenue: $0.00+0.0%|EPS: $-0.06-92.7%N/AForm 10-K/A - FY 2023
Period End: Dec 31, 2023|Filed: Apr 29, 2024|Revenue: $0.00+0.0%|EPS: $-1.30+24.4%N/A